These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 31064025)

  • 1. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
    Adamkewicz JI; Chen DC; Paz-Priel I
    Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays.
    Adamkewicz JI; Kiialainen A; Paz-Priel I
    Int J Lab Hematol; 2020 Apr; 42(2):e71-e75. PubMed ID: 31670901
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.
    Kitazawa T; Esaki K; Tachibana T; Ishii S; Soeda T; Muto A; Kawabe Y; Igawa T; Tsunoda H; Nogami K; Shima M; Hattori K
    Thromb Haemost; 2017 Jun; 117(7):1348-1357. PubMed ID: 28451690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
    Kitazawa T; Shima M
    Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
    Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
    Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
    Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
    Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.
    Müller J; Pekrul I; Pötzsch B; Berning B; Oldenburg J; Spannagl M
    Thromb Haemost; 2019 Sep; 119(9):1384-1393. PubMed ID: 31203578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
    Ogiwara K; Furukawa S; Shinohara S; Tabuchi Y; Arai N; Noguchi-Sasaki M; Soeda T; Shima M; Nogami K
    Haemophilia; 2023 Jan; 29(1):329-335. PubMed ID: 36137299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
    Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
    Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
    Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
    J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
    Lenting PJ; Denis CV; Christophe OD
    Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma.
    Tripodi A; Chantarangkul V; Novembrino C; Scalambrino E; Boscolo-Anzoletti M; Clerici M; Rossi F; Peyvandi F
    Clin Chem Lab Med; 2020 Sep; 59(2):365-371. PubMed ID: 32892172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bispecific antibody demonstrates limited measurability in routine coagulation assays.
    Hartmann R; Feenstra T; Knappe S; Schrenk G; Scheiflinger F; Dockal M
    Blood Coagul Fibrinolysis; 2020 Sep; 31(6):353-365. PubMed ID: 32467424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
    Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
    J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
    Yada K; Nogami K
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.